NCCN 2012 Congress Series: Genitourinary Cancers™
This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most up-to-date treatment recommendations for these cancers. As research continues in these areas and new information emerges, it is critical that clinicians are kept up-to-date and informed. This congress will communicate the NCCN Guidelines in a direct and interactive way to community oncologists and other clinical professionals.
Target Audience
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this congress, participants should be able to:
Kidney Cancer
- Summarize the role of surgical management in localized and resectable advanced kidney cancer
- Apply existing and emerging clinical research data to make evidence-based selection of front-line and subsequent therapy for advanced renal cell cancer
Bladder Cancer
- Recognize the role of adjuvant intravesical therapy in non-invasive bladder cancer management
- Describe the role of chemotherapy and radiation therapy in the treatment of invasive bladder cancer
- Summarize the role of bladder preservation in the management of invasive bladder cancer
- Apply existing and emerging clinical research data to make evidence-based selection of front-line and subsequent therapy for treatment of bladder cancer to maintain the best possible quality of life
Prostate Cancer
- Counsel patients with localized prostate cancer on the appropriate therapeutic options based on individual risk assessment
- Describe novel agents approved for advanced disease
- Outline patient selection criteria for the proper use of novel agents in advanced disease
- Outline the use and benefits of radiation therapy in various disease settings
Agenda
7:15 – 8:00 AM
Registration, Breakfast, and Exhibits
8:00 – 8:10 AM
Welcome
Peter E. Clark, MD
Vanderbilt-Ingram Cancer Center
KIDNEY CANCER
8:10 – 8:55 AM
Surgical Management of Localized Kidney Cancer and Resectable Advanced Disease
Sam S. Chang, MD
Vanderbilt-Ingram Cancer Center
9:00 – 9:45 AM
Targeted Therapy Options in Unresectable and Recurrent Kidney Cancer
Toni K. Choueiri, MD
Dana-Farber/Brigham and Women's Cancer Center
9:45 – 10:05 AM
Break and Exhibits
BLADDER CANCER
10:05 – 11:00 AM
Treatment of Non-Metastatic Bladder Cancer
Peter E. Clark, MD
Vanderbilt-Ingram Cancer Center
11:05 – 11:50 AM
Treatment of Advanced Bladder Cancer
Lance C. Pagliaro, MD
The University of Texas MD Anderson Cancer Center
11:50 AM – 12:50 PM
Lunch and Exhibits
PROSTATE CANCER
12:50 – 1:35 PM
Risk Assessment for Locoregional Prostate Cancer
James L. Mohler, MD
Roswell Park Cancer Institute
1:40 – 2:25 PM
Treatment of Advanced Prostate Cancer
Sandy Srinivas, MD
Stanford Cancer Institute
2:30 – 3:15 PM
Radiation Therapy in Prostate Cancer
Michael Kuettel, MD, MBA, PhD
Roswell Park Cancer Institute
3:15 PM
Closing Remarks
This Congress is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided for all sessions. Please view the complete accreditation details for additional information.
Available Credit
- 5.50 Participation
- 5.42 Nurse
- 5.50 Pharmacist
- 5.50 Physician